This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
This open-label, randomized, prospective, controlled 52-week trial matched 49 patients with multiple sclerosis for demographic and disease characteristics, with randomization to 25 in treatment or 24 in control groups. High-dose vitamin D (∼10,000 IU/d) in multiple sclerosis was safe, with evidence of immunomodulatory effects.
See p. 1852; Editorial, p. 1846
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
In this phase II treatment-combination study in 30 subjects with multiple sclerosis (MS), rituximab was effective at improving the rate of new MRI …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease
Reduced bone resorption and increased bone mineral density in women with restless legs syndrome
Association between restless legs syndrome and other movement disorders
Treatment of restless legs syndrome with pregabalin